Navigating SCAN Health Plan Skyrizi Prior Authorization

Understanding SCAN Health Plan's Prior Authorization Framework

SCAN Health Plan, like other Medicare Advantage and managed care organizations, employs a structured prior authorization process for high-cost specialty medications. This framework is designed to ensure medical necessity aligns with clinical guidelines and formulary preferences. For drugs such as Skyrizi, which often involve chronic conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, the review process is rigorous. Clinics and hospitals must be prepared to submit comprehensive clinical documentation to support the requested therapy.

Skyrizi-Specific Clinical Criteria and Documentation for SCAN

Approvals for Skyrizi (risankizumab) are contingent upon meeting specific diagnostic and treatment history criteria, typically aligned with evidence-based guidelines from organizations like the American Academy of Dermatology or the American College of Rheumatology. SCAN Health Plan will assess the patient's diagnosis (e.g., ICD-10 codes L40.0 for psoriasis, M07.0 for psoriatic arthritis, K50.X for Crohn's, K51.X for ulcerative colitis), prior therapeutic trials (e.g., failure or contraindication to conventional systemic therapies or other biologics), and disease severity. Comprehensive medical records, including relevant lab results, imaging reports, and physician notes detailing disease activity and previous treatment responses, are essential for a successful submission. CPT codes related to administration and diagnosis must also be accurate.

Electronic Prior Authorization (ePA) Pathways for SCAN

Submitting prior authorizations electronically offers advantages in speed and auditability. SCAN Health Plan supports various ePA methods, including direct submission via their provider portal, third-party clearinghouses like Availity or CoverMyMeds, and potentially through integrated EHR solutions. The X12 278 transaction set is the HIPAA-compliant standard for electronic healthcare service information requests, including prior authorizations. Ensuring your organization's ePA system is configured for accurate data exchange with SCAN, whether direct or via a clearinghouse, is paramount for reducing manual processing and potential denials. The NCPDP SCRIPT standard may also be relevant for pharmacy benefit authorizations.

Key Documentation Elements for Skyrizi PA Submissions

• Patient demographics and insurance information, including SCAN Health Plan member ID.
• Prescribing physician's NPI and contact details.
• Specific ICD-10 diagnosis code(s) supporting medical necessity.
• Relevant CPT codes for the medication and administration, if applicable.
• Detailed clinical notes outlining diagnosis, disease severity, and current symptoms.
• Documentation of previous treatment failures or contraindications to alternative therapies.
• Lab results (e.g., CRP, ESR, liver function tests, TB screening) and imaging reports.
• Patient weight and height for dosing calculations, if applicable.
• Date of initiation and requested duration of therapy.

Navigating Denial and the Peer-to-Peer (P2P) Process

Despite meticulous submissions, initial denials can occur. Understanding the specific reason for denial is the first step in the appeals process. Common denial reasons include insufficient documentation, failure to meet medical necessity criteria (e.g., per MCG or InterQual guidelines), or lack of prior therapeutic trial. The peer-to-peer (P2P) review process allows the prescribing physician to discuss the case directly with a SCAN Health Plan medical director. This interaction often provides an opportunity to present additional clinical context or clarify aspects of the patient's care that may not have been fully captured in the initial submission. Preparing the P2P discussion with clear, concise clinical arguments is critical.

Impact on Revenue Cycle Management and Patient Access

Delays or denials in prior authorization for specialty drugs like Skyrizi directly impact a clinic's revenue cycle and patient care continuity. Extended turnaround times can lead to delayed treatment initiation, potentially affecting patient outcomes and satisfaction. From a financial perspective, unauthorized services result in claims denials, increased administrative burden for appeals, and lost revenue. Proactive management, including real-time eligibility and benefit verification, coupled with robust ePA workflows, mitigates these risks. Integration of PA data within existing EHRs like Epic Hyperspace or Cerner PowerChart also enhances data consistency and reduces manual entry errors.

Leveraging Technology for Prior Authorization Efficiency

Modern prior authorization platforms and interoperability standards offer significant operational advantages. SMART on FHIR applications can integrate directly with EHR systems to pull necessary clinical data for PA submissions, reducing manual chart abstraction. The Da Vinci PAS (Prior Authorization Support) Implementation Guide, built on FHIR, aims to automate the exchange of prior authorization information between providers and payers, moving towards a more automated, real-time process. Adopting these technologies can significantly reduce the administrative overhead associated with managing complex authorizations, improving both efficiency and compliance with evolving regulatory mandates like CMS-0057-F.